Association of A³¹³G glutathione S-transferase P1 germline polymorphism with susceptibility to de novo myelodysplastic syndrome

Abstract

Models for the pathogenesis of myelodysplastic syndrome (MDS) imply the role of individual genetic variations in genes involved in detoxification mechanisms. GSTP1 enzyme plays a key role in the biotransformation of a variety of carcinogens. The corresponding gene is subject to a single nucleotide polymorphism (A³¹³G) leading to abolished enzyme activity. In order to evaluate whether the GSTP1 polymorphism influences MDS susceptibility, we conducted a case–control study comprising 310 de novo patients and 370 healthy controls using a real-time polymerase chain reaction (PCR) genotyping method. The GSTP1 gene status was also evaluated in relation to patients’ characteristics and chromosomal abnormalities. A significantly higher incidence of the GSTP1 variant genotypes was observed in patients with MDS compared to controls (p < 0.0001). The results revealed increased frequencies of heterozygotes in patients younger than 60 years old and of homozygotes G/G in older patients (p = 0.007). Our results provide evidence for a pathogenetic role of the GSTP1 polymorphism in MDS risk, probably in an age-dependent manner.

Keywords::

• Myelodysplastic syndromes (MDS)
• glutathione S-transferase P1 (GSTP1)
• genetic susceptibility
• single nucleotide polymorphism (SNP)
• oxidative stress

Acknowledgements

The authors wish to thank Prof. P. Kollia for her valuable suggestions. We acknowledge E. M. Delicha for statistical analysis; and K. Stavropoulou and V. Diamantopoulou for excellent technical assistance.

Potential conflict of interest:

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

This work has been co-financed by the European Union (European Social Fund, ESF) and Greek National funds through the Operational Program “Education and Lifelong Learning” of the NSRF-Research Funding Program “Heracleitus II.”